Posted by Michael Wonder on 13 Sep 2024
Health Canada approves Keytruda as monotherapy for the treatment of adult and paediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumours that have progressed following prior treatment and who have no satisfactory alternative treatment options
12 September 2024 - Merck announced that Health Canada has granted approval of Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, as a monotherapy for the treatment of adult and paediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumours, as determined by a validated test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
This approval is based on the results from Phase 2 KEYNOTE-158, KEYNOTE-164, and KEYNOTE-051 trials, and includes data from 504 patients across more than 30 cancer types.
